Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nSf-CoVac
- Development stage
- Preclinical
- Lead developer
- Sferogen
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
nSf-CoVac is a monovalent protein nanoparticle vaccine candidate developed by Sferogen for the prevention of COVID-19. It utilizes Sferogen's proprietary nanoSFERIC platform, which is designed to present SARS-CoV-2 antigens in a highly organized nanoparticle format to elicit a robust and protective immune response. Unlike Sferogen's CoVLP candidate, which is based on enveloped virus-like particles (eVLP), nSf-CoVac employs a protein nanoparticle architecture. The vaccine is intended to enhance the stability and immunogenicity of viral antigens compared to traditional protein subunit approaches. As of the current pipeline status, nSf-CoVac is in the preclinical research and development stage.
- Other names
- nanoSFERIC/SARS-CoV-2nSf-CoVac (monovalent)nanoSFERIC protein nanoparticle vaccine-COVID-19
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on nSf-CoVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nSf-CoVac.